These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35914365)

  • 41. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
    Edgar JE; Trezise S; Anthony RM; Krammer F; Palese P; Ravetch JV; Bournazos S
    Proc Natl Acad Sci U S A; 2023 Oct; 120(44):e2314905120. PubMed ID: 37871218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
    Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
    PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
    Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
    Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.
    Liu Q; Xue C; Zheng J; Liu K; Wang Y; Wei Y; Liu GD; Cao Y
    Vaccine; 2015 Jul; 33(32):4035-40. PubMed ID: 26100927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
    Carreño JM; Strohmeier S; Kirkpatrick Roubidoux E; Hai R; Palese P; Krammer F
    mBio; 2020 Dec; 11(6):. PubMed ID: 33323511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, Synthesis and Primary Immunologic Evaluation of M2e-CRM
    Xu L; Zhang C; Zhang J; Yu R; Su Z
    Curr Pharm Biotechnol; 2021 Oct; 22(14):1910-1918. PubMed ID: 33148152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.
    Padilla-Quirarte HO; Badillo-Godinez O; Gutierrez-Xicotencatl L; Acevedo-Betancur Y; Luna-Andon JD; Montiel-Hernandez JL; Lopez-Guerrero DV; Esquivel-Guadarrama F
    Vaccine; 2019 May; 37(19):2624-2633. PubMed ID: 30955979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
    Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
    Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.
    Lee YN; Lee YT; Kim MC; Gewirtz AT; Kang SM
    J Immunol; 2016 Mar; 196(6):2637-45. PubMed ID: 26864033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.
    Schotsaert M; Ysenbaert T; Neyt K; Ibañez LI; Bogaert P; Schepens B; Lambrecht BN; Fiers W; Saelens X
    Mucosal Immunol; 2013 Mar; 6(2):276-87. PubMed ID: 22806098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Ko EJ; Lee Y; Lee YT; Kim YJ; Kim KH; Kang SM
    Antiviral Res; 2018 Aug; 156():107-115. PubMed ID: 29885376
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanoparticles based on artificial self-assembling peptide and displaying M2e peptide and stalk HA epitopes of influenza A virus induce potent humoral and T-cell responses and protect against the viral infection.
    Zykova AA; Blokhina EA; Stepanova LA; Shuklina MA; Tsybalova LM; Kuprianov VV; Ravin NV
    Nanomedicine; 2022 Jan; 39():102463. PubMed ID: 34583058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.
    Elaish M; Ngunjiri JM; Ali A; Xia M; Ibrahim M; Jang H; Hiremath J; Dhakal S; Helmy YA; Jiang X; Renukaradhya GJ; Lee CW
    PLoS One; 2017; 12(2):e0171174. PubMed ID: 28151964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.